ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics Securities Fraud Lawsuit

The Schall Law Firm reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. for violations of securities laws.

Apr. 7, 2026 at 2:34pm

Got story updates? Submit your updates here. ›

A minimalist studio still life photograph featuring a stack of legal documents, a gavel, and a pair of reading glasses, conceptually representing a securities fraud lawsuit against a pharmaceutical company.A legal case against a pharmaceutical company's alleged securities fraud aims to recover losses for impacted investors.Los Angeles Today

The Schall Law Firm, a national shareholder rights litigation firm, is reminding investors of a class action lawsuit against Aldeyra Therapeutics, Inc. for violations of securities laws. The lawsuit covers the period from November 3, 2023 to March 16, 2026, and investors who purchased the company's securities during this time are encouraged to contact the firm to participate in the case.

Why it matters

The lawsuit alleges that Aldeyra Therapeutics made false and misleading statements to the market about the results of clinical trials for its reproxalap drug candidate, which suffered from inconsistencies. This resulted in the company's public statements being false and materially misleading, causing investor losses when the truth was revealed.

The details

According to the complaint, Aldeyra Therapeutics violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated by the U.S. Securities and Exchange Commission. The lawsuit covers the period from November 3, 2023 to March 16, 2026, and investors who purchased the company's securities during this time are encouraged to contact the Schall Law Firm to participate in the case.

  • The class period is from November 3, 2023 to March 16, 2026.
  • Investors have until May 29, 2026 to contact the Schall Law Firm to participate in the case.

The players

Aldeyra Therapeutics, Inc.

A biopharmaceutical company that develops and commercializes medicines for the treatment of immune-mediated diseases.

The Schall Law Firm

A national shareholder rights litigation firm that specializes in securities class action lawsuits and shareholder rights litigation.

Got photos? Submit your photos here. ›

What they’re saying

“We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.”

— Brian Schall, Attorney, Schall Law Firm

What’s next

The class in this case has not yet been certified, and until certification occurs, investors are not represented by an attorney. Investors who suffered a loss are encouraged to contact the Schall Law Firm before May 29, 2026 to discuss their rights and participate in the case.

The takeaway

This lawsuit highlights the importance of transparency and accuracy in public statements made by publicly traded companies. Investors who suffered losses due to Aldeyra Therapeutics' alleged false and misleading statements about its drug candidate have the opportunity to seek recourse through this class action lawsuit.